Sign in

    Cooper Companies Inc (COO)

    You might also like

    The Cooper Companies, Inc. is a global medical device company operating through two main business segments: CooperVision and CooperSurgical. CooperVision focuses on the vision correction market, developing, manufacturing, and marketing a wide range of soft contact lenses, including products like the MiSight 1 day lens, which is FDA-approved for slowing myopia progression in children . CooperSurgical specializes in fertility and women's health, offering products and services such as medical devices, fertility products, cryostorage services, and contraception solutions like the PARAGARD IUD . The company continues to expand its market presence through strategic acquisitions and product innovations in both segments .

    1. CooperVision - Develops, manufactures, and markets a wide range of soft contact lenses, including spherical, toric, multifocal, and myopia management lenses.
      • MiSight 1 day lens - FDA-approved lens designed to slow myopia progression in children.
      • MyDay - A product line contributing significantly to the company's revenue.
      • Biofinity - Another key product line in the vision correction market.
    2. CooperSurgical - Focuses on fertility and women's health, offering a diverse portfolio of products and services.
      • Fertility Products - Includes medical devices and cryostorage services.
      • Contraception Solutions - Features products like the PARAGARD IUD.
    NamePositionStart DateShort Bio
    Albert G. White IIIPresident & Chief Executive OfficerMay 2018Albert G. White III has served as the President & Chief Executive Officer of The Cooper Companies, Inc. since May 2018. He previously held roles such as Chief Financial Officer and Executive Vice President and Chief Strategy Officer. Before joining Cooper, he was a Director with KeyBanc Capital Markets .
    Daniel G. McBrideExecutive Vice President & Chief Operating OfficerNovember 2013Daniel G. McBride has served as the Executive Vice President and Chief Operating Officer since November 2013. He has held various roles within the company, including interim General Counsel and Secretary, and President of CooperVision. Before joining Cooper, he was an attorney with Latham & Watkins LLP .
    Brian G. AndrewsExecutive Vice President, Chief Financial Officer & TreasurerDecember 2020Brian G. Andrews has served as Executive Vice President, Chief Financial Officer & Treasurer since December 2020. He has been with the company in various capacities since January 2013. Before joining Cooper, he held corporate and investment banking positions at KeyBanc Capital Markets and ING Barings .
    Agostino RicupatiSenior Vice President, Finance & Tax / Chief Accounting OfficerOctober 2017Agostino Ricupati has served as the Senior Vice President, Finance & Tax / Chief Accounting Officer since October 2017. Before joining Cooper, he was the International Tax Director at Intel Corp. and has over 20 years of experience in senior finance and tax roles .
    Nicholas S. KhadderVice President, General Counsel & Corporate SecretaryAugust 2022Nicholas S. Khadder has served as Vice President, General Counsel & Secretary since August 2022. Before joining Cooper, he was the general counsel of Standard BioTools, Inc. and held various positions at Amyris, Inc. He began his legal career as a corporate attorney at Fenwick & West LLP .
    Holly R. SheffieldPresident, CooperSurgical, Inc.July 2020Holly R. Sheffield has served as the President of CooperSurgical, Inc. since July 2020. Before this role, she was the Executive Vice President & Chief Strategy Officer. She has over 20 years of experience in investment banking, including positions at UBS Securities LLC and Credit Suisse .
    Gerard H. Warner IIIPresident, CooperVision, Inc.February 2022Gerard H. Warner III has served as the President of CooperVision, Inc. since February 2022. Prior to this role, he was the Executive Vice President, Americas & Global Commercial Functions of CooperVision. Before joining CooperVision, he spent 17 years at Bausch + Lomb in various marketing and management roles .
    1. Given the unexpected revenue softness at the end of Q4 and the potential impact of recent price increases, can you provide more detail on how your pricing strategy is affecting consumer buying behavior and what measures you're taking to mitigate any potential negative effects on revenues?

    2. With competitors accelerating their product launches and expanding their portfolios, how confident are you in your current pipeline and global launch strategy to maintain and grow your market share, and can you elaborate on specific new products or innovations that will differentiate you in fiscal 2025?

    3. You mentioned that CooperSurgical faced challenges with the Q2 IT system upgrade that impacted operations; can you discuss how these issues affected your financial performance and operational efficiency, and what steps have been implemented to prevent similar disruptions in the future?

    4. Considering that the recent acquisitions contributing approximately $25 million in annualized revenue are now part of the organic base and the M&A environment is currently quiet, how do you plan to drive growth organically in fiscal 2025, and what strategies are in place to compensate for the reduced contribution from acquisitions?

    5. While you've indicated minimal exposure to tariffs from manufacturing in China, Mexico, or Canada, how are you assessing and mitigating potential supply chain and geopolitical risks in other regions where you have manufacturing facilities to ensure uninterrupted operations and protect your margins?

    Program DetailsProgram 1
    Approval DateMarch 2017
    End Date/DurationN/A
    Total Additional Amount$1.0 billion
    Remaining Authorization$256.4 million
    DetailsThe 2012 Share Repurchase Program was amended in March 2017 to increase the authorization to $1.0 billion. The program allows repurchases as permitted by securities laws and has no expiration date.
    YearAmount Due (in billions)Debt TypeInterest Rate (%)% of Total Debt
    20240.033Short-term DebtN/A1.3% = (0.033 / 2.5837) * 100
    20261.52021 Term Loan Facility5.9458.1% = (1.5 / 2.5837) * 100
    20291.0492024 Revolving Credit Facility6.0540.6% = (1.049 / 2.5837) * 100

    Competitors mentioned in the company's latest 10K filing.

    • Johnson & Johnson Vision Care, Inc. - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories .
    • Alcon Inc. - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories .
    • Bausch + Lomb - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories .
    • Vitrolife Group - Competitor in the fertility market .
    • FujiFilm-Irvine Scientific - Competitor in the fertility market .
    • Hamilton Thorne - Competitor in the fertility market .
    • Fairfax Cryobank and Fairfax EggBank - Competitors in the fertility market .
    • ViaCord, a division of Revvity - Competitor in the stem cell storage field in the United States .
    • Bayer - Competitor with hormonal IUDs .
    • AbbVie - Competitor with hormonal IUDs .
    • Organon - Competitor with Long Acting Reversible Contraceptives .
    • Medtronic - Competitor with medical device products .
    • Hologic - Competitor with medical device products .
    NameStart DateEnd DateReason for Change
    KPMG LLP1982 PresentCurrent auditor

    Recent developments and announcements about COO.

    Financial Reporting

      Earnings Call

      ·
      Dec 6, 2024, 3:59 AM

      Cooper Companies recently held their Fourth Quarter and Full Year 2024 Earnings Conference Call, where they reported record revenues of $3.9 billion for fiscal 2024, with both CooperVision and CooperSurgical achieving record revenues . For the fourth quarter, consolidated revenues were $1.018 billion, marking a 10% increase year-over-year . CooperVision's quarterly revenues were $676 million, up 9%, driven by strong performance in silicone hydrogel dailies and multifocals . CooperSurgical reported revenues of $342 million, up 12%, with significant growth in fertility services .

      Looking forward to fiscal 2025, Cooper Companies expects the contact lens market to grow by 5% to 7% in constant currency, with CooperVision aiming to grow by 6.5% to 8.5% . They anticipate price increases to offset inflation, contributing to about one-third of this growth . CooperSurgical is expected to see mid-single-digit organic growth, with fertility services projected to grow in the high single digits .

      Management highlighted strategic initiatives such as expanding manufacturing capacity, optimizing technology investments, and launching new products . They also discussed the sustainability of the pricing environment in the contact lens market, expecting it to offset inflationary pressures .

      During the Q&A session, analysts inquired about consumer price sensitivity and the adoption of daily silicone hydrogel lenses, with management noting consistent growth across their product portfolio . They also addressed questions about the competitive landscape and the impact of new product launches on market share .

      Overall, Cooper Companies is focused on leveraging their market-leading products and improving operational efficiencies to drive growth in fiscal 2025 .

      Earnings Report

      ·
      Dec 5, 2024, 9:44 PM

      CooperCompanies (Nasdaq: COO) has released its financial results for the fiscal fourth quarter and full year ended October 31, 2024. Here are the key highlights from the earnings release:

      • Fourth Quarter 2024 Revenue: The company reported revenue of $1,018.4 million, marking a 10% increase from the previous year, or 7% organically. The fiscal year 2024 revenue was $3.9 billion, up 8% both reported and organically .

      • Earnings Per Share (EPS): The GAAP diluted EPS for the fourth quarter was $0.58, a 38% increase from the previous year. For the full fiscal year, the GAAP diluted EPS was $1.96, up 33%. The non-GAAP diluted EPS for the fourth quarter was $1.04, up 19%, and for the fiscal year, it was $3.69, up 15% .

      • Operating Margins: The operating margin for the fourth quarter was 19%, up from 15% in the previous year, driven by SG&A expense leverage and stronger gross margins. On a non-GAAP basis, the operating margin was 26%, up from 24% last year .

      • CooperVision Revenue: The revenue for CooperVision was $676.4 million, up 9% from the previous year, with a constant currency growth of 8%. The revenue growth was consistent across different product categories and geographies .

      • CooperSurgical Revenue: The revenue for CooperSurgical was $342.0 million, up 12% from the previous year, with a constant currency growth of 12% and organic growth of 5% .

      • Free Cash Flow: The company generated a free cash flow of $128.2 million for the fourth quarter, after accounting for capital expenditures of $139.9 million .

      Al White, Cooper's President and CEO, expressed optimism about the company's performance, highlighting record revenues and non-GAAP EPS, and expressed confidence in continued success in fiscal 2025 .

      These results indicate strong financial performance and growth across CooperCompanies' business units, driven by strategic initiatives and market conditions.